Janssen Submits Crohn’s Disease Drug STELARA for Approval in the United States and European Union

Janssen Submits Crohn’s Disease Drug STELARA for Approval in the United States and European Union
Janssen Biotech, Inc. and Janssen-Cilag International NV, both part of the Janssen Pharmaceutical Companies of Johnson & Johnson, recently announced the submission of the company’s product STELARA® (ustekinumab), developed as a potential treatment for moderate to severe Crohn’s disease in adult patients, to the U.S. Food and Drug Administration (FDA)’s Biologics License Application (BLA) and

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *